Revium Rx.

Clinical/early-stage biotech — clinical-stage biotech micro-cap, funded.

Strengths

• Liquidity — current ratio 2.3 (30th)

Risks

• Pre-revenue, deep losses — per metrics
• Pre-revenue/clinical-stage — history of losses & need for capital per risk factors
• Binary clinical & funding risk — per 10-K

Notable findings

• Exec changeRecent 8-K item 5.02 8-K ↗